Rheumatologist Receives Scleroderma Foundation's Lifetime Achievement Award PDF Print E-mail
Thursday, 17 September 2009 10:52
In a recent Medical News Today article, it was reported that Thomas A. Medsger Jr., M.D.,  Gerald P. Rodnan Professor of Medicine, University of Pittsburgh School of Medicine, received the Scleroderma Foundation's Lifetime Achievement Award in recognition of his service to the Scleroderma community. The award is the foundation's highest honor and is presented to individuals who have devoted a minimum of 20 years of service, either as a volunteer or professional, to the Scleroderma community.

Dr. Medsger has served as chief of the University of Pittsburgh's Division of Rheumatology and Clinical Immunology, and director of the Scleroderma Research Program and UPMC's Scleroderma Clinic. His primary clinical and investigative interest is in Scleroderma and other connective tissue diseases.

In 2001 and 2005, Dr. Medsger was the recipient of the Scleroderma Foundation's Doctor of the Year award. He also has been designated as one of the Best Doctors in America by American Health Magazine for the past two decades and was the recipient of the American College of Rheumatology's Distinguished Rheumatologist Award. Recently, he had the title of "Master" conferred upon him by the American College of Rheumatology - a title awarded to members of high professional competence, ethics and moral standing who have significantly furthered the science of rheumatology.

Dr. Medsger currently serves as the Scleroderma Foundation Western Pennsylvania Chapter's treasurer and interim president. He has written numerous articles for the Foundation's Voice magazine and has published more than 300 journal articles about scleroderma and related diseases.

Read the full article here.
 
More articles :

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...

» Our Donors

The Scleroderma Care Foundation wishes to express our appreciation and gratitude for the generosity and support extended to us, by all of our donors to date, and the list keeps on growing. Your contributions have all been incredibly helpful and...

» What Causes Scleroderma?

Collagen is a group of naturally occurring proteins, found exclusively in animals and especially in the flesh and connective tissues of mammals. It is the main component of connective tissue, and is the most abundant protein in mammals, constituting...

» Positive Phase II Results for AIMSPRO In Scleroderma Announced

announced yesterday, positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic...

» NeoStem Awarded Grant To Develop New Treatment for Skin Wounds In Scleroderma

NeoStem, as a leader in the emerging cellular therapy industry, announced that it had received an award under the Small Business Innovative Research Program of $147,765 for the “Development of Adult Pluripotent Very Small Embryonic Like (VSEL)...

» Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma

Researchers in Italy evaluated 65 patients with Juvenile Localized (JLS; or) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg...